Fundraising Fox

Remepy

Founded 2022 · 86 employees on LinkedIn · 11 known investors

Find your way into Remepy

89 people in our graph share verified history with the Remepy team — schools, employers, funds. One of them is your warm intro.

Lior Elovitchunlockedknows Or Shoval · together at Israeli Military Intelligence (overlapped)
×10knows the team · via Israeli Military Intelligence
knows the team · via Remepy

Remepy develops "Hybrid Drugs" that combine pharmaceuticals with targeted digital interventions to deliver personalized and adaptive therapies for patients. It operates in the digital health and biotech space, aiming to treat conditions through a combination of biology, behavior, and technology.

AI & Machine LearningBiotechDigital Health

Founders & leadership

Remepy was founded in 2022 by Or Shoval.

OSOr Shoval
Or ShovalinCo-Founder & Co-CEOCo-founder and co-CEO of Remepy, which develops hybrid therapies combining pharmaceuticals with digital interventions to treat patients through integrated biological and behavioral mechanisms.

Investors · 11

97212 VenturesNew York · $150K – $500K
fresh.fund
IT-Farm CorporationTokyovia Julien Nguyen · inferred
NFXSan Francisco · $250K – $5M
O.G. Venture PartnersTel Aviv-Yafo · $5M – $15M
PsyMed VenturesBerkeley
Samsung NextSan Jose · $100K – $5M
Supernode VenturesNew York · $500K – $1.3M
Vine VenturesNew York · $1M – $10M
Key1 CapitalreportedHerzliya
Qumra CapitalreportedTel Aviv · $15M – $30M

Funding

SEC filings, press & company announcements

$36M disclosed across 1 of 2 rounds · 2026

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 3

by search overlap
Bioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Biosapien3 shared keywordsBiosapien develops treatments for cancer that are delivered locally to shrink tumors, relieve symptoms, and reduce the need for surgeries.
Remedy Plan3 shared keywordsRemedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer. Its lead clinical candidate, RPT1G, is a hyperbolic inhibitor designed to reduce NAMPT activity while avoiding the toxicity that has limited earlier attempts.

Companies competing with Remepy for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Remepy Raises $36 Million Series A, Bringing Total Funding To $62 Million As Parkinson's Hybrid Drug Heads Toward Phase IIIpulse2.com · Aug 2026Remepy Raises $36M in Series A Fundingfinsmes.com · Aug 2026Merck KGaA partner Remepy raises USD 36m Series A for 'hybrid drug' platformallsci.com · Aug 2026Remepy raises $36 million Series A as it prepares AI-driven Parkinson’s treatment for Phase III | CTechcalcalistech.com · Aug 2026Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Diseaseprnewswire.com · Aug 2026Remepy raises $36M to pair prescription drugs with therapeutic softwareaxios.com · Aug 2026

Frequently asked questions

What does Remepy do?
Remepy develops "Hybrid Drugs" that combine pharmaceuticals with targeted digital interventions to deliver personalized and adaptive therapies for patients. It operates in the digital health and biotech space, aiming to treat conditions through a combination of biology, behavior, and technology.
Who founded Remepy?
Remepy was founded by Or Shoval in 2022.
Who are Remepy's investors?
Remepy's investors include 97212 Ventures, fresh.fund, IT-Farm Corporation, NFX, O.G. Venture Partners, PsyMed Ventures, Samsung Next, Supernode Ventures and 3 more.
How much funding has Remepy raised?
Remepy has disclosed $36M raised across 1 of its 2 known rounds.